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Introduction
Sarcopenia is defined as an age-related disease of 
low muscle mass and low muscle strength or function 
(1). Sarcopenia is of increasing clinical importance due to 
growing evidence of its health implications and the increasing 
proportion of older people in the population. Sarcopenia has 
been associated with an increased risk and rate of falls (2), 
fractures (3), functional impairment (2), metabolic syndrome 
(4), hospital admission and readmission (2, 5) poorer prognosis 
in cancer (6) and liver cirrhosis (7), surgical morbidity (8) 
and all-cause mortality (2, 6). The clinical significance of 
sarcopenia as a distinct disease entity was established with the 
assignment of an International Classification of Diseases, Tenth 
Revision, Clinical Modification (ICD-10-CM) code (M62.84) 
in September 2016 (9).
A 2017 systematic review and meta-analysis including 35 
studies with 58,404 individuals estimated that the prevalence 
of sarcopenia globally was 10% in both men and women, and 
higher among non-Asian than Asian individuals (10). Others 
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existing operational definition of sarcopenia. In Phase 3, 94.4% of respondents voted in favour of adopting the 
European Working Group on Sarcopenia in Older People (EWGSOP) definition as the operational definition 
for sarcopenia in Australia and New Zealand. Conclusion: With consensus achieved, the ANZSSFR will adopt, 
promote and validate the EWGSOP operational definition of sarcopenia for use by clinicians and researchers in 
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have reported the prevalence of sarcopenia to range from 1-29% 
in community-dwelling populations, 14-33% in long-term 
care populations and 10% in acute hospital settings (11). This 
marked heterogeneity is largely due to the different definitions 
applied to diagnose sarcopenia (12). Nevertheless, as the global 
population ages, the number of sarcopenic older adults is 
projected to increase substantially over the coming decades. 
As such, research is needed to help alleviate the burden of 
sarcopenia. For this to be effective, a clear consensus of what 
defines sarcopenia needs to be established.
Several operational definitions of sarcopenia have been 
developed (1, 13, 17) since the term was first coined almost 30 
years ago (18). The most widely used operational definitions, 
combining both low muscle mass and function, are described 
in Appendix 1. While there is widespread agreement on 
sarcopenia as a disease entity, there is no uniform consensus 
regarding the operational definition of sarcopenia. This leads to 
challenges in comparing results from research studies utilising 
different definitions of sarcopenia, and undoubtedly is a source 
of confusion for both researchers and clinicians. Indeed, only 
one in five health care professionals know how to diagnose 
sarcopenia using the operational definitions available (19).
The most widely utilised consensus definition of sarcopenia 
in the research literature was developed by the European 
Working Group on Sarcopenia in Older People (EWGSOP) 
in 2010 (1). The EWGSOP definition includes an algorithm 
comprising gait speed, handgrip strength and muscle mass 
with cut-points dependent upon the individual’s demographics 
(sex and height) (1). In 2014, this definition was modified 
and validated by the Asian Working Group on Sarcopenia in 
recognition of the impact ethnic differences have on cut-points 
for muscle mass, strength and performance (17).
The establishment of a demographically-appropriate 
operational definition of sarcopenia is required to unify 
researchers and provide clear guidance to clinicians for 
the diagnosis and treatment of sarcopenia (20). A group of 
individuals with an interest or expertise in sarcopenia were 
invited to join a Task Force and participate in a consensus-
building collaboration with the aim of establishing an 
operational definition of sarcopenia for use by researchers and 
clinicians in Australia and New Zealand. 
Methods 
A four-Phase modified Delphi method was employed 
to achieve consensus amongst Task Force members on the 
preferred operational definition of sarcopenia for use in 
Australia and New Zealand (Figure 1). The Delphi method 
supports the structuring of group communication to allow a 
group of individuals to, as a collective, deal with complex 
problems and reach consensus (21). The modified Delphi 
method (22) employed by the Task Force allowed for face-to-
face communication in Phase 1 and approval of final statements 
in Phase 4. The Task Force leaders (GD, DS, JZ) designed and 
modified the questionnaires in Phases 2 and 3. The modified 
Delphi method used by the Australian and New Zealand Society 
for Sarcopenia and Frailty Research (ANZSSFR) Task Force 
adhered to preferred reporting methods and procedures (23).
Figure 1
Flow Chart of modified Delphi Method
ANZSSFR  - Australian and New Zealand Society for Sarcopenia and Frailty Research. 
2RQ – Second-round Questionnaire.  3RQ – Third-round Questionnaire. n = number of 
respondents
Selection of Task Force members 
A group of individuals with an interest or expertise 
in sarcopenia (physicians, geriatricians, primary and post-
doctoral researchers, allied health professionals, health 
service managers) were invited to participate in a focus group 
discussion and form a Task Force to achieve consensus on 
the operational definition of sarcopenia in Australia and New 
Zealand. Prior to the first meeting, participants were provided 
with an overview, background, aims, strategies and 17 key 
references related to the different operational definitions of 
sarcopenia (Appendix 2). 
Phase 1 – Face-to-face meeting 
On November 26th, 2017 following the ANZSSFR Scientific 
Meeting in Adelaide, Australia, 19 of the 24 invited Task Force 
members met for a four-hour meeting. Two presentations were 
delivered by researchers to the Task Force (DS and EMR) 
who summarized the key issues and outlined the agenda. Two 
focus groups were formed with key discussion points including 
whether the Task Force should adopt an existing definition 
or establish a new definition of sarcopenia, and to identify 
knowledge gaps in sarcopenia research. The de-identified 
minutes of the meeting are attached as Appendix 3 and 
informed the Second Round Questionnaire (2RQ). 
Phase 2 – Online Questionnaire 
On December 20th, 2017 an online, anonymous 
questionnaire (2RQ) developed by GD, DS and JZ was 
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circulated to 23 Task Force members. The minutes of Phase 
1 were provided to Task Force members. The pre-specified 
level of agreement (80%) required for consensus was selected 
by the Task Force Leaders based on recommended practice 
(24, 25) and comparable modified Delphi studies (26). The 
methodology was outlined to Task Force members who were 
given three weeks to complete the 2RQ. A total of 12 questions 
and statements were contained in the 2RQ, which included four 
statements or key questions, four demographic questions and 
four free-text questions, attached as Appendix 4. The findings 
of the 2RQ informed the development of the Third Round 
Questionnaire (3RQ). 
Phase 3 – Online Questionnaire 
On February 26th, 2018 an online, anonymous questionnaire 
(3RQ) informed by the 2RQ and developed by GD, DS and 
JZ was circulated to 24 Task Force members who were given 
three weeks to complete the 3RQ. The results of the 2RQ were 
provided verbatim to Task Force members. A total of three 
statements and questions and four demographic questions were 
included in the 3RQ (Appendix 5). 
Phase 4 – Circulation of position paper
The results of the 3RQ were provided verbatim to Task 
Force members. The statements and questions accepted to 
the pre-specified level of agreement in Phases 2 and 3 were 
circulated amongst Task Force members. Task Force members 
were requested to vote on a single statement contained within 
the position paper.
Statistical Analysis 
Statistical analysis was undertaken using the pre-specified 
level of agreement (>80%) required to accept a statement. 
Statements or questions that did not reach a level of agreement 
greater than 80% but achieved moderate agreement (70-80%) 
in 2RQ were re-examined in 3RQ, consistent with comparable 
modified Delphi methodologies (26). Due to the size of the 
Task Force in addition to the small number of questions and 
statements being examined, investigation of dispersion or 
heterogeneity was not undertaken as is often performed in 
larger modified Delphi method studies (26).
Results 
A total of 19/24 Task Force members participated in Phase 
1. Due to one drop-out from Phase 1, 23 Task Force members 
were surveyed in Phase 2. In Phase 3, 24 individuals were 
surveyed following the re-joining of a Task Force member. 
Response rates in Phases 2 (n=17, 73.9%) and 3 (n=18, 75.0%) 
were similar. Due to de-identification, it is unknown whether 
there was consistency in responding Task Force members in 
Phases 2 and 3. The demographic details of participating Task 
Force members in Phases 2 and 3 are illustrated in Table 1.  
In total, two statements regarding the operational definition 
of sarcopenia were accepted to a level greater than 80% 
and five were rejected (28.6% acceptance rate). Questions, 
statements and respective levels of agreement in each Phase 
are listed in Table 2. In Phase 2, 94.1% of respondents agreed 
that “an existing operational definition for sarcopenia should 
be adopted and validated using existing Australian and New 
Zealand data sets.” Agreement on a preferred definition of 
sarcopenia was moderate in Phase 2, with 70.6% of respondents 
supporting the EWGSOP definition (1), 17.6% supporting the 
Foundation for the National Institute of Health Biomarkers 
Consortium Sarcopenia Project (FNIH) definition (16), and 
11.8% supporting other (13) or new definitions. Consensus 
was not achieved (76.5%) on the adoption and promotion of 
the sarcopenia screening tool, SARC-F (27), for use by primary 
care clinicians.
Table 1
Demographics of Task Force members in Phases 2 and 3
Variable Phase 2 (n = 17) Phase 3 (n = 18)
Mean age, years (SD) 42.5 (10.3) 44.2 (10.2)
Gender, n (Female, %) 5 (29.4%) 6 (33.3%)
State or Country (n) 
  New South Wales 1 1
Victoria 10 10
Queensland 1 1
South Australia 2 2
Western Australia 1 3
New Zealand 1 1
Position or Role (n) 
Primary clinical researcher 7 10
Post-doctoral researcher 2 2
Physician/geriatrician 5 4
Allied health 1 1
Health service manager 2 1
SD = Standard Deviation
In Phase 3, 94.4% of respondents agreed to adopt the 
EWGSOP operational definition of sarcopenia. Consensus 
was not achieved on whether the ANZSSFR should adopt 
and promote the accepted operational definition in its current 
form, including established cut-points, or await validation 
studies among Australian and New Zealand populations. There 
was moderate agreement (72.2%) amongst respondents that 
an established definition should be adopted and promoted 
immediately, with cut-points for sarcopenia components 
(e.g. muscle mass, muscle strength and gait speed) modified 
should future validation studies suggest this is necessary for 
Australian and New Zealand populations. Conversely, 22.2% 
of respondents agreed that the promotion of an established 
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definition should await validation studies, while 5.6% of 
respondents agreed that an existing definition including cut-
points should be adopted and promoted in its entirety without 
need for further validation among Australian and New Zealand 
populations.
In Phase 4, Task Force members were presented with a 
position paper and surveyed on their agreement with the 
statement posed in 3RQ, that the ANZSSFR should adopt 
and promote the EWGSOP and its established cut-points and 
modify these cut-points if validation studies suggest this as 
necessary. There was 100% agreement from 23 respondents to 
this statement. 
Discussion 
To date, a definition of sarcopenia has not been specifically 
developed for, or validated in, Australian and New Zealand 
populations. Across the globe, demographic differences have 
resulted in various measurement cut-points (17), therefore the 
ANZSSFR Task Force on Sarcopenia was formed to achieve 
Table 2
Non-free text questions, statements and respective levels of agreement 
Questions and Statements Respondents, n (% of invitation) Agreement (%) Outcome
Phase 2
5. An existing operational definition for sarcopenia should be adopted and validated using existing 
Australian and New Zealand data sets
17 (73.9%) 94.1% Accepted
6. If the adoption of an existing definition is the majority opinion of the Task Force, which operational 
definition of sarcopenia do you prefer?
• EWGSOP 12 (52.2%) 70.6% Informed 3RQ
• FNIH 3 (13.0%) 17.7%
• Other 2 (8.7%) 11.8%
8. If the ANZSSFR proposes to develop a new definition with Aus./NZ data on the basis of these survey 
results, please provide suggestions for the proposed methodology (eg. Measurement tools; cut-points 
etc.).
• I do not support an additional definition therefore do not wish to comment 9 (39.2%) 52.9% Rejected
• Preferred methodology / cut-points 8 (34.8%) 47.1%
9. Should the society consider recommending the SARC-F as a screening tool for GPs, allied health and 
other health professionals?
• Yes 13 (56.5%) 76.5% Informed 3RQ
• No 4 (17.4%) 23.5%
Phase 3
5. Which operational definition of sarcopenia should the ANZSSFR adopt?
• EWGSOP 17 (70.1%) 94.4% Accepted EWGSOP
• FNIH 1 (4.2%) 5.6%
6. The ANZSSFR should;
• Adopt and promote an established definition in its entirety (including its existing cut-points) 1 (4.2%) 5.6% Informed Phase 4
• Adopt and promote an established definition and modify this in future if subsequent validation studies 
suggest different cut-points are more appropriate in Australia and New Zealand
13 (54.2%) 72.2%
• Await the validation studies of Aus./NZ cohorts prior to adopting and promoting a definition 4 (16.7%) 22.2%
7. The pre-specified level of agreement (80%) was not reached to adopt the SARC-F as a recommen-
dation for a screening tool for GPs and other allied health professionals (77%). To further explore this 
question, should the ANZSSFR;
• Recommend the SARC-F as a screening tool for GPs, allied health and other health professionals at 
the present time
6 (25%) 33.3% Rejected
• Not include SARC-F in its recommendations at the present time 1 (94.2%) 5.6%
• Consider SARC-F in the future when consensus is achieved on the preferred operational definition of 




1. The ANZSSFR Task Force should promote the EWGSOP definition in our activities directed at 
clinicians and researchers. However, a key objective for the Task Force in future will be to establish 
appropriate cut-points for appendicular lean muscle mass, handgrip strength and gait speed in Australian 
and New Zealand populations using data from local cohort studies.
23 (95.8%) 100.0% Accepted
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consensus on an operational definition of sarcopenia for use 
by researchers and clinicians in Australia and New Zealand. 
Leading researchers in sarcopenia have called for a consensus 
definition (20), a sentiment echoed in Phase 1 of the Delphi 
method undertaken by the Task Force. Task Force members 
achieved consensus in Phase 2 of the Delphi method to adopt 
and validate an existing definition of sarcopenia, rather than 
develop a new definition in Australia and New Zealand. The 
consensus to adopt the EWGSOP operational definition of 
sarcopenia reflects the fact that this is currently the most cited 
definition of sarcopenia worldwide (1).
While consensus was achieved on the adoption of the 
EWGSOP operational definition of sarcopenia, the timing of 
when to promote the definition fell short of the pre-specified 
level of agreement in Phase 3. A majority of respondents 
(72.2%) in Phase 3 agreed that the EWGSOP definition should 
be promoted immediately and subsequent validation studies 
should determine whether diagnostic cut-points need to be 
modified. Consensus on this statement was achieved in Phase 4 
with agreement of 100%. Therefore the ANZSSFR Task Force 
have achieved consensus for the immediate promotion of the 
EWGSOP definition in its activities directed at researchers 
and clinicians. A key objective for the Task Force will be to 
determine whether appropriate cut-points for muscle mass, 
handgrip strength and gait speed can be established using 
data from local cohort studies if the EWGSOP cut-points are 
found not to be predictive of sarcopenia-related outcomes 
in Australian and New Zealand older adult populations (1). 
Australia and New Zealand are comprised of ethnically diverse, 
indigenous and immigrant populations to whom existing 
sarcopenia definitions and cut-points may not apply. The Asian 
Working Group on Sarcopenia previously adopted modified 
cut-points for the EWGSOP definition reflective of differences 
in muscle mass and strength observed between Asian and 
European older adults (18). Our Task Force will also promote 
sarcopenia research in Australia and New Zealand’s diverse 
populations to determine whether different cut-points are 
required in different ethnic groups within our countries. Further, 
if these validation studies or further research in sarcopenia 
suggest other measures of muscle mass, muscle strength and 
physical performance are superior to those adopted, additional 
examination of the definition by the Task Force may be 
required. 
In clinical practice, diagnostic tools such as dual energy 
X-ray absorptiometry (DXA), bioimpedance analysis (BIA) 
and handgrip strength dynamometers may not be immediately 
available to the clinician. A screening tool for sarcopenia, 
SARC-F, was developed for use by clinicians and was found to 
be valid for predicting adverse outcomes in sarcopenia (27). A 
recent meta-analysis demonstrated that the SARC-F had poor 
sensitivity but high specificity for predicting those that should 
undergo further diagnostic testing for sarcopenia (28). While 
the majority (61.1%) of respondents reported a decision should 
be made on the use of SARC-F following further research, 
only 33.3% supported the immediate adoption and promotion 
of this tool for use as a screening device in the Australia and 
New Zealand. Therefore, the Task Force will advocate for 
further research on SARC-F in Australia and New Zealand and 
re-evaluate support for the SARC-F as a screening tool in the 
future. 
A Delphi method may be limited by the breadth and diversity 
of its participants and rate of responses. In this modified Delphi 
method, a broad range of Task Force members across Australia 
and New Zealand were involved, however this process was 
limited by low or no representation from some Australian 
states. This Delphi method was strengthened by response 
rates in Phases 2, 3 and 4 exceeding 70% and the release of 
results verbatim to Task Force members. While preference 
exists for the involvement of patients or consumers in a Delphi 
method (23), the complexity and depth of knowledge required 
to judiciously answer questions and statements required 
experts in the field of sarcopenia, particularly given the low 
levels of public awareness of sarcopenia. Nevertheless, future 
activities for this Task Force will seek to engage clinicians and 
consumers.
The development of this consensus definition has the 
potential to unify researchers across Australia and New Zealand 
and assist with further international collaborations. In addition, 
the provision of a consistent definition and message to primary 
care clinicians and the aged care and long-term care sectors, 
where prevalence is at its highest, may increase diagnosis and 
treatment of sarcopenia. 
Conclusion
The ANZSSFR will adopt and promote the EWGSOP 
operational definition of sarcopenia in Australia and New 
Zealand however the ANZSSFR acknowledges further 
research is required to validate the definition in this setting. 
This is a significant step towards regional and international 
consensus on sarcopenia in the understanding of this disease. 
Validation studies will be undertaken using this definition 
among specific regional and ethnic populations, and may result 
in future recommendations which provide adapted cut-points 
for individual components of sarcopenia. Any future variations 
to the current EWGSOP definition will be considered and 
evaluated by the ANZSSFR Task Force prior to adoption and 
validation. 
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